

Remedi's COVID-19 pandemic response outlined here includes communication, procedures and other resources to keep our customers and employees safe as they continue to care for those we mutually serve.

KEY DATES AND COMMUNICATION

MARCH 5, 2020

1st Memo to Customers

- Drug Availability
- Maintaining Pharmacy Operations
- Disaster Planning Policies and Procedures
- Additional Resources

MARCH 10, 2020

1st Memo to Delivery Drivers and Dispatchers

- Infection Control – Personal and handheld devices
- Self-screening and facility screening

MARCH 17, 2020

2nd Memo to Customers

- Infection Control and Alternative Delivery Procedures

MARCH 23, 2020

3rd Memo to Customers

- Medication Delivery – Disposable totes, driver/staff safe distancing
- Returns, e-kits, IV pumps

MARCH 25, 2020

4th Memo to Customers

- Hydroxychloroquine and Azithromycin

MARCH 26, 2020

5th Memo to Customers

- Nebulized drugs and inhalers

MARCH 29, 2020

Ventricular Arrhythmia Risk Due to Hydroxychloroquine Azithromycin Treatment for COVID-19 (*Cardiology Magazine*)

APRIL 10, 2020

ASHP COVID-19 Evidence Table

APRIL 15, 2020

Therapeutic Options Dosing Guide for Hydroxychloroquine and Azithromycin

APRIL 15, 2020

Drugs That May Prolong QTc Interval Reference Guide



COVID-19

PROCEDURES/ADVANTAGES FOR REMEDI CUSTOMERS



Every **R**esident
Every **E**mployee
Every **M**inute
Every **E**xperience
Every **D**ollar
Every **I**nteraction

Everyday Advantages

- PAXIT® cart organization - fewer cart touches*
- Recyclable packaging - one touch and done - no repeated contact as with punch cards*
- Reduced waste with daily delivery
- Prompt regulatory support
- Retrospective billing
- Elastomeric pumps versus reusable IV pumps*
- LOA medications*
- Streamlined 'go-live' options*
- Pharmacy open 24/7/365
We never close
- Reduced med pass time

*Infection Control Measure

Enhanced Pandemic Advantages

- Contact-free delivery*
- Disposable delivery bags in lieu of reusable totes*
- Disposable thermal bags for refrigerated medications*
- Available consolidated delivery*
- IV pump management - disposable IV Flow Regulators (Dial-a-Flow) for hydrations and other basic IV therapies*
- Recommendations for management of nebulized medications and inhaler therapies*
- Increased education and regulatory guidance
- Remote drug regimen reviews
 - Optimize med pass efficiency*

EMPLOYEE SAFETY AND WELL-BEING

- Keeping employees informed with weekly communication from CEO
- Screening of employee and delivery personnel
- Wearing face masks
- Implementing enhanced policies/procedures around workplace cleanliness and sanitization
- Practicing social distancing
- Providing resources/websites for employees (CDC, WHO, CMS, BOP)
- Expanding infection control processes



COVID-19

OTHER RESOURCES AVAILABLE TO REMEDI CUSTOMERS

• Regulatory Guidance Webinar

Title: The clinical, operational and regulatory impact of COVID-19 on pharmacy services and medication management.

Description: Despite the unprecedented challenges facing long-term care providers, resident safety dictates that the core functions surrounding medication management and pharmacy services remain a priority. This 30-minute webinar shares best practices related to drug management, medication pass optimization, consultant pharmacist collaboration and regulatory compliance.



• MyRemedi® Web-based portal

- Real-time data
- Infection Control Resources



• Remedi Website

www.RemediRx.com/covid-19

• Quick Reference Guides

- Staging Procedures
- Staging Posters
- Refrigerated Items
- Conservation of PPE
- Cleaning of Delivery Area in Times of Increased Risk
- Social Distancing
- Wash Your Hands Fact Sheet
- Cleaning Electronic Equipment
- IV Pump Cleaning Instructions
- Flow Regulator
- IV Rate Calculations
- Replacement of OSS Doses during Emergency Period
- Compressing Bags/Consolidated Bags
- CMS Part D Signature Waiver
- State-Specific Board of Pharmacy Orders
- DEA Guidance on Oral Schedule II Controlled Substance Prescriptions
- COVID-19 Emergency Verbal C2 Options
- FDA Final Hydroxychloroquine and Chloroquine LOA Authorizations

